ArticleAntimicrobial agents and chemotherapy2020

Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Vidmantas Petraitis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.